Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High – What’s Next?

Posted by Brenda Bartman on Aug 13th, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $36.65 and last traded at $36.46, with a volume of 1273185 shares traded. The stock had previously closed at $34.42.

Wall Street Analyst Weigh In

PHVS has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Citizens Jmp cut their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Morgan Stanley raised their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. Finally, Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $50.08.

Read Our Latest Research Report on PHVS

Pharvaris Price Performance

The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -11.47 and a beta of -2.31. The stock has a 50 day moving average price of $33.59 and a two-hundred day moving average price of $30.01.

Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Sell-side analysts forecast that Pharvaris N.V. will post -2.97 EPS for the current fiscal year.

Insider Activity at Pharvaris

In other news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the transaction, the director owned 315,167 shares of the company’s stock, valued at $11,185,276.83. This represents a 8.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Anne Lesage sold 27,872 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.48, for a total transaction of $988,898.56. Following the transaction, the insider owned 58,750 shares in the company, valued at approximately $2,084,450. The trade was a 32.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 178,322 shares of company stock valued at $5,969,286 over the last quarter. 11.84% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after buying an additional 15,769 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares in the last quarter. Amundi raised its holdings in shares of Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after purchasing an additional 7,879 shares in the last quarter.

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.